HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible deterioration in payer mix and a revision to full-year profitability guidance triggered immediate target cuts across Wall Street. In its Q2 results, HCA Healthcare, Inc. reported that revenue increased 8.7% year-over-year to $20.23 billion from $18.61 billion in Q2 2025.
The firm's net income attributable to the company rose 2.8% to $1.69 billion, while diluted EPS increased 11.6% to $7.62 (or $7.59 on an adjusted basis). Adjusted EBITDA grew 4.6% to $4.027 billion compared to $3.849 billion in the prior-year period. Operational volume remained positive overall, with same-facility admissions up 2.5%, equivalent admissions up 2.7%, and emergency room visits rising 3.6%.
However, same-facility inpatient surgeries dropped 2.3%, and outpatient surgeries fell 3.4%. Despite the top-line expansion, management was forced to adjust its full-year 2026 outlook downward. The company now expects 2026 diluted EPS of $28.70 to $30.50 (down from $29.10 to $31.50) and Adjusted EBITDA of $15.40 billion to $16.10 billion (down from $15.55 billion to $16.45 billion), while narrowing revenue guidance to $77.00 billion to $79.50 billion.
The primary culprit was a policy-driven payer mix shift: an uptick in uninsured volume following Medicaid redeterminations and the lapse of health insurance exchange coverage wiped out roughly $400 million from Q2 pre-tax income. HCA now anticipates the full-year exchange-related drag to reach $1.00 billion to $1.20 billion, partially offset by $300 million to $500 million in net Medicaid Supplemental Payment Program benefits. Following the report, analysts swiftly adjusted their models.
On July 28, Mizuho lowered its price target on HCA to $475 from $525 while keeping an Outperform rating, citing slower post-Q2 growth expectations. The same day, Morgan Stanley reduced its price target to $380 from $425 and maintained an Underweight rating. Morgan Stanley analyst noted that while lower guidance "puts numbers in a better place," core EBITDA performance was "disappointing," warning of a full valuation alongside a rising risk profile in payer mix.
This brings up a key question: Does HCA Healthcare, Inc. (NYSE:HCA)'s guidance cut and payer mix pressure mark a structural breakdown in its earnings narrative, or is this temporary volatility creating an attractive entry point into the nation's largest hospital network? Optimistic investors point to HCA Healthcare, Inc.'s unmatched operating scale and market density. Operating 190 hospitals and roughly 2,600 ambulatory sites of care across 19 states and the UK, HCA commands superior bargaining power with commercial payers and medical suppliers.
Extract — continue reading at the source.
